The DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Open accessAbstract
Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, affecting 20%-25% of the adult population. In 25% of patients, nonalcoholic fatty liver disease progresses to nonalcoholic steatohepatitis (NASH), which increases the risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma. In patients with NASH, liver fibrosis is the main determinant of mortality. Here, we review how interactions between different liver cells culminate in fibrosis development in NASH, focusing on triggers and consequences of hepatocyte-macrophage-hepatic stellate cell (HSC) crosstalk. We discuss pathways through which stressed and dead hepatocytes instigate the profibrogenic crosstalk with HSC and macrophages, including the reactivation of developmental pathways such as TAZ, Notch, and hedgehog; how clearance of dead cells in NASH via efferocytosis may affect inflammation and fibrogenesis; and insights into HSC and macrophage heterogeneity revealed by single-cell RNA sequencing. Finally, we summarize options to therapeutically interrupt this profibrogenic hepatocyte-macrophage-HSC network in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [9]
In the citing paper
“The perisinusoidal fibrosis in early human NASH is thought to be produced by activated HSCs/myofibroblasts.114”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [114]
In the citing paper
“The disease-driving pathways of NASH converge in fibrosis (Fig. 3), an aberrant wound-healing process resulting not only in scarring (extracellular matrix deposition), but also in the loss of functional hepatocytes and chronic inflammation.104”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [104]
In the citing paper
“The disease-driving pathways of NASH converge in fibrosis (Fig. 3), an aberrant wound-healing process resulting not only in scarring (extracellular matrix deposition), but also in the loss of functional hepatocytes and chronic inflammation.104”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [104]
In the citing paper
“Furthermore, monocytes and macrophages are capable of remarkable functional plasticity, displaying diverse phenotypes during wound healing dependent on multiple cues including the environmental niche61,62 and the temporal stage of tissue injury and repair63–66.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“demonstrated that the absence of Lyve1hiMHCIIlo IMs exacerbates experimental lung fibrosis, thereby showing that two independent populations of IMs coexist across tissues with conserved niche-dependent functional programs61.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“Two independent IM subpopulations that are conserved across lung, fat, heart, and dermis were identified: (Lyve1loMHCIIhiCX3CR1hi (Lyve1loMHCIIhi) and Lyve1hiMHCIIloCX3CR1lo (Lyve1hiMHCIIlo) monocyte-derived IMs.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
In the citing paper
“Several recent studies have identified subpopulations of monocytes and macrophages which have the capacity to regulate fibrosis and tissue remodelling18,61,68–71.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., Garner, H., Trouillet, C., de Bruijn, M. F., Geissmann, F., et al. (2015) · Nature · doi:10.1038/nature13989 · Cited by 2,339
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citation
Research works printed but not linked: 2
- Mooring, 2019, Hepatocyte stress increases expression of YAP and TAZ in hepatocytes to promote parenchymal inflammation and fibrosis, Hepatology
- Song, 2019, YAP in Kupffer cells enhances the production of pro-inflammatory cytokines and promotes the development of non-alcoholic steatohepatitis, Hepatology
Cited by
Sorted by citations
Items 101–200 of 679
Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways
Yong, Q., Huang, C., Chen, B., An, J., Zheng, Y., Zhao, L., Peng, C., & Liu, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116952 · Cited by 40
Wang, X., & Peng, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.655557 · Cited by 42
GARP on hepatic stellate cells is essential for the development of liver fibrosis
Zhang, X., Sharma, P., Maschmeyer, P., Hu, Y., Lou, M., Kim, J., Fujii, H., Unutmaz, D., Schwabe, R. F., & Winau, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.043 · Cited by 42
Self-citationSingle cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module
Bendixen, S. M., Jakobsgaard, P. R., Hansen, D., Hejn, K. H., Terkelsen, M. K., Bjerre, F. A., Thulesen, A. P., Eriksen, N. G., Hallenborg, P., Geng, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.001 · Cited by 40
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 45
Liu, X., Cai, Y., Zhang, Y., Zhang, H., Tian, S., Gong, Y., Song, Q., Chen, X., Ma, X., Wen, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107526 · Cited by 39
Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 40
Luo, X., Zhang, B., Pan, Y., Gu, J., Tan, R., & Gong, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893561 · Cited by 40
When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosis
Ferdek, P. E., Krzysztofik, D., Stopa, K. B., Kusiak, A. A., Paw, M., Wnuk, D., & Jakubowska, M. J. (2022) · The Journal of Physiology · doi:10.1113/jp281135 · Cited by 38
Lan, T., Chen, B., Hu, X., Cao, J., Chen, S., Ding, X., Li, S., Fu, Y., Liu, H., Luo, D., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117516 · Cited by 37
Purinergic Signaling in Liver Pathophysiology
Jain, S., & Jacobson, K. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718429 · Cited by 37
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Ezzo, M., & Hinz, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108528 · Cited by 39
Zhou, L., Lu, Y., Qiu, X., Chen, Z., Tang, Y., Meng, Z., Yan, C., Du, H., Li, S., & Lin, J. D. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115310 · Cited by 41
c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis
Leslie, J., Macia, M. G., Luli, S., Worrell, J. C., Reilly, W. J., Paish, H. L., Knox, A., Barksby, B. S., Gee, L., Zaki, M. Y. W., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00306-2 · Cited by 36
Self-citationRole of Exosomes in Chronic Liver Disease Development and Their Potential Clinical Applications
Wang, C., Liu, J., Yan, Y., & Tan, Y. (2022) · Journal of Immunology Research · doi:10.1155/2022/1695802 · Cited by 37
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Friedman, S. L. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0240 · Cited by 37
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis
Subramanian, P., Gargani, S., Palladini, A., Chatzimike, M., Grzybek, M., Peitzsch, M., Papanastasiou, A. D., Pyrina, I., Ntafis, V., Gercken, B., et al. (2021) · Hepatology · doi:10.1002/hep.32153 · Cited by 34
Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
Song, C., Long, X., He, J., & Huang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1081334 · Cited by 34
Vargas-Pozada, E. E., Ramos‐Tovar, E., Acero-Hernández, C., Cardoso-Lezama, I., Galindo‐Gómez, S., Tsutsumi, V., & Muriel, P. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100671 · Cited by 34
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
“45 As the GLP-1R is not expressed on hepatic stellate cells, 17 and BemA treatment attenuates TGF-b -mediated activation of both murine and human hepatic stellate cells in vitro , 22 this direct effect on hepatic stellate cells may be important for reducing fibrosis.”
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
Xu, J., Li, Y., Feng, Z., & Chen, H. (2025) · Cells · doi:10.3390/cells14030221 · Cited by 37
Cell-in-Cell Structures in the Liver: A Tale of Four E’s
Davies, S. P., Terry, L. V., Wilkinson, A. L., & Stamataki, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00650 · Cited by 33
Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells
Manka, P. P., Coombes, J. D., Sydor, S., Swiderska‐Syn, M., Best, J., Gauthier, K. C., van Grunsven, L. A., Oo, Y. H., Wang, C., Diehl, A. M., et al. (2023) · Liver International · doi:10.1111/liv.15759 · Cited by 33
Li, J., Li, J.-Z., Li-hong, Y., Ni, L., Huang, X., Liang, X., Zhang, H.-C., Liu, Z., Zhang, X., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.16125 · Cited by 36
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
Geng, Y., & Schwabe, R. F. (2025) · Hepatology · doi:10.1097/hep.0000000000001386 · Cited by 34
Self-citationValenzuela‐Vallejo, L., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155246 · Cited by 32
Zhang, M., Barroso, E., Peña, L., Rada, P., Valverde, Á. M., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117303 · Cited by 31
Fang, Q., Li, X., Wang, M., Qiao, X., Huang, F., Hu, C., Xue, Y., Zhao, S., & Lin, Y. (2022) · Food & Function · doi:10.1039/d2fo00012a · Cited by 31
The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
Winarto, J., Song, D., & Pan, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098203 · Cited by 34
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31
Marqués, P., Francisco, V., Martínez‐Arenas, L., Carvalho‐Gomes, Â., Domingo, E., Piqueras, L., Berenguer, M., & Sanz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032313 · Cited by 31
Gong, Y., Liu, Z., Zhang, Y., Zhang, J., Yin, Z., & Wu, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01477-z · Cited by 32
Myokines: Crosstalk and Consequences on Liver Physiopathology
Dumond, A., Potier, J.-B., Pinget, M., & Bouzakri, K. (2023) · Nutrients · doi:10.3390/nu15071729 · Cited by 30
Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes
Shi, T., Kobara, H., Oura, K., & Masaki, T. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s274933 · Cited by 29
Márquez-Quiroga, L. V., Arellanes‐Robledo, J., Vásquez-Garzón, V. R., Villa‐Treviño, S., & Muriel, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114845 · Cited by 29
Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights
Xia, Y., Yan, M., Wang, P., Hamada, K., Yan, N., Hao, H., Gonzalez, F. J., & Yan, T. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000455 · Cited by 29
Hepatocyte SREBP signaling mediates clock communication within the liver
Guan, D., Bae, H., Zhou, D., Chen, Y., Jiang, C., La, C. M., Xiao, Y., Zhu, K., Hu, W., Trinh, T. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163018 · Cited by 28
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
Valenzuela‐Vallejo, L., Sanoudou, D., & Mantzoros, C. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050830 · Cited by 31
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Cernea, S. (2024) · Life · doi:10.3390/life14020272 · Cited by 30
Luo, J., Li, L., Chang, B. Y., Zhu, Z., Deng, F., Hu, M., Yu, Y., Lu, X., Chen, Z., Zuo, D., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.03.011 · Cited by 30
Wang, Y., Zhou, J., Yang, Q., Li, X., Qiu, Y., Zhang, Y., Liu, M., & Zhu, A. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100635 · Cited by 28
MyD88 in Macrophages Enhances Liver Fibrosis by Activation of NLRP3 Inflammasome in HSCs
Ge, S., Yang, W. P., Chen, H., Yuan, Q., Liu, S., Zhao, Y., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212413 · Cited by 29
KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7
Yang, S., Jia, L., Xiang, J., Yang, G., Qiu, S., Kang, L., Zheng, P., Liang, Z., & Lü, Y. (2022) · EMBO Reports · doi:10.15252/embr.202154229 · Cited by 28
Nickel, S., Christ, M., Schmidt, S., Kosacka, J., Kühne, H., Roderfeld, M., Longerich, T., Tietze, L., Bosse, I., Hsu, M., et al. (2022) · Cells · doi:10.3390/cells11111829 · Cited by 28
Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
Subramanian, P., Hampe, J., Tacke, F., & Chavakis, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136996 · Cited by 35
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Li, Y., Hu, H., Yang, H., Lin, A., Xia, H., Cheng, X., Kong, M., & Liu, H. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100892 · Cited by 26
Sommerauer, C., & Kutter, C. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2022 · Cited by 27
Cardoso-Lezama, I., Fuentes-Figueroa, M. Á., Ramos‐Tovar, E., Márquez-Quiroga, L. V., Ortiz‐Fernández, A., Vargas-Pozada, E. E., Arellanes‐Robledo, J., Tsutsumi, V., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115762 · Cited by 27
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Bai, W., & Zhu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1720780 · Cited by 34
Heo, Y. J., Choi, S., Lee, N., Jeon, J. Y., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15465 · Cited by 25
Deacetylation of Notch1 by SIRT1 contributes to HBsAg- and HBeAg-mediated M2 macrophage polarization
Li, J., Yu, M., Zong, R., Fan, C., Ren, F., Wu, W., & Li, C. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00338.2021 · Cited by 26
Mechanisms of ductular reaction in non-alcoholic steatohepatitis
Chen, Y., Gao, W.-K., Shu, Y.-Y., & Ye, J. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i19.2088 · Cited by 25
Shen, Z., Shen, B., Dai, W., Zhou, C., Luo, X., Guo, Y., Wang, J., Xu, X., Sun, Z., Cai, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106572 · Cited by 26
Sui, Y., Lu, Y., Zuo, S., Wang, H., Bian, X., Chen, G., Huang, S., Dai, H., Liu, F., & Dong, H. (2022) · Toxins · doi:10.3390/toxins14120840 · Cited by 24
Wang, S., Gao, J., Yang, M., Zhang, G., Yin, L., & Tong, X. (2024) · Advanced Science · doi:10.1002/advs.202405678 · Cited by 26
Key role of macrophages in the progression of hepatic fibrosis
Ran, J., Yin, S., Issa, R., Zhao, Q., Zhu, G., Zhang, H., Zhang, Q., Wu, C., & Li, J. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000602 · Cited by 25
Carson, J. P., Robinson, M. W., Ramm, G. A., & Gobert, G. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06774-3 · Cited by 27
Yokosaki, Y., & Nishimichi, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312794 · Cited by 24
Enomoto, M., Kaji, K., Nishimura, N., Fujimoto, Y., Murata, K., Takeda, S., Tsuji, Y., Fujinaga, Y., Takaya, H., Kawaratani, H., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.04.012 · Cited by 24
Ikeda, S., Sugihara, T., Hoshino, Y., Matsuki, Y., Nagahara, T., Okano, J., Kitao, S., Fujioka, Y., Yamamoto, K., & Isomoto, H. (2020) · Yonago acta medica · doi:10.33160/yam.2020.08.009 · Cited by 25
Li, Y., Xiu, W., Xu, J., Chen, X., Wang, G., Duan, J., Sun, L., Liu, B., Xie, W., Pu, G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.162402 · Cited by 23
Liu, Y., Chen, H., Yan, X., Zhang, J., Deng, Z., Huang, M., Gu, J., & Zhang, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01489-x · Cited by 23
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Yu, S., Wang, J., Zheng, H., Wang, R., Johnson, N. L., Li, T., Li, P., Lin, J., Li, Y., Jin, Y., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s377768 · Cited by 24
The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03595-1 · Cited by 24
Lv, H., Jiang, Y., Zhu, G., Liu, S., Wang, D., Wang, J., Zhao, K., & Liu, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-28351-3 · Cited by 23
Grove, J. I., Lo, P. C. K., Shrine, N. R. G., Barwell, J., Wain, L. V., Tobin, M. D., Salter, A. M., Borkar, A. N., Ocaña, S. C., Bennett, N., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100764 · Cited by 24
Bacil, G. P., Romualdo, G. R., Rodrigues, J., & Barbisan, L. F. (2023) · Food Research International · doi:10.1016/j.foodres.2023.113513 · Cited by 23
Macrophage metabolism in nonalcoholic fatty liver disease
Zhang, W., & Lang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257596 · Cited by 28
Growth differentiation factor 15: Emerging role in liver diseases
Li, Y., Zhang, J., Chen, S., Ke, Y., Ke, Y., & Chen, Y. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156727 · Cited by 23
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
Stoess, C., Leszczynska, A., Kui, L., & Feldstein, A. E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1218807 · Cited by 24
Zhang, W., Lu, J., Feng, L., Xue, H., Shen, S., Lai, S., Li, P., Li, P., Kuang, J., Yang, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45520-8 · Cited by 22
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 25
IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism
Azuma, Y., Fujita, T., Izawa, T., Hirota, K., Nishiyama, K., Ikegami, A., Aoyama, T., Ike, M., Ushikai, Y., Kuwamura, M., et al. (2021) · Cells · doi:10.3390/cells10123513 · Cited by 21
Bi, C., Xiao, G., Liu, C., Yan, J., Chen, J., Si, W., Zhang, J., & Liu, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702414 · Cited by 25
Amzolini, A. M., Forțofoiu, M.-C., Abu-Alhija, A. B., Vladu, I. M., Clenciu, D., Mitrea, A., Forţofoiu, M., Matei, D. V., Enăchescu, V., Predescu, O. I., et al. (2022) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.62.2.13 · Cited by 23
Chen, Z., Ding, C., Gu, Y., He, Y., Chen, B. Y., Zheng, S., & Li, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120515 · Cited by 22
Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-β production
Song, J., Lv, H., Liu, B., Hao, M., Taylor, H. S., Zhang, X., Li, D., & Huang, Y. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101828 · Cited by 23
Qin, M., Li, J., Zheng, Y.-T., Li, Y.-J., Zhang, Y., Ou, R.-X., He, W.-Y., Zhao, J.-M., Liu, S.-T., Liu, M., et al. (2023) · Food & Function · doi:10.1039/d3fo03858k · Cited by 22
Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
Fernández-Ginés, R., Encinar, J. A., Escoll, M., Carnicero-Senabre, D., Jiménez-Villegas, J., García‐Yagüe, Á. J., González‐Rodríguez, Á., García‐Martinez, I., Valverde, Á. M., Rojo, A. I., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103027 · Cited by 23
Bi, T., Liang, P., Zhao, Q., Wu, J., Zhou, Y., Xu, Y., Fan, X., Yang, G., Sun, Q., Ren, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02658 · Cited by 21
Alsaqal, S., Hockings, P. D., Ahlström, H. K., Gummesson, A., Hedström, A., Hulthe, J., Johansson, L., Niessen, H. G., Schoelch, C., Schultheis, C., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28040 · Cited by 22
Hany, N. M., Eissa, S., Basyouni, M., Hasanin, A. H., Aboul-Ela, Y. M., Magd, N. M. A. E., Montasser, I. F., ALI, M. A. M., Skipp, P. J. S., & Matboli, M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03543-z · Cited by 23
Fang, Q., Qiao, X., Yin, X., Zeng, Y.-C., Du, C., Xue, Y., Zhao, X.-J., Hu, C., Huang, F., & Lin, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114160 · Cited by 23
Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary
Villani, R., Lupo, P., Sangineto, M., Romano, A. D., & Serviddio, G. (2023) · Diagnostics · doi:10.3390/diagnostics13071236 · Cited by 21
Yang, S., Xu, B., Han, Y., Jiang, M., Luo, T., Wu, N., Cao, J., Zheng, Y., Shen, L., Qin, W., et al. (2023) · Liver International · doi:10.1111/liv.15607 · Cited by 21
Zhang, T., Wang, C., Song, A., Xiao, L., Li, G., Sun, H. M., Wang, X., Geng, Z., Shu, G., & Deng, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117495 · Cited by 21
Mašek, J., & Andersson, E. R. (2024) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2023.102302 · Cited by 25
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 21
Zhang, L., Liu, Z., Liu, Y., Chen, Y., Chen, J., & Lu, C. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07952 · Cited by 20
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 22
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 25
Devan, A. R., Nair, B., Kumar, A. R., & Nath, L. R. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2123 · Cited by 22
Mitochondrial folate metabolism–mediated α-linolenic acid exhaustion masks liver fibrosis resolution
Gao, Y., Zheng, B., Xu, S., Zhao, Z., Liu, W., Wang, T., Yuan, M., Sun, X., Tan, Y., Xu, Q., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104909 · Cited by 21
Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease
Li, Y., Yunrui, L. U., Mozuo, N. I. A. N., Sheng, Q., ZHANG, C., Han, C. Q., Dou, X., & Ding, Y. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60443-1 · Cited by 21
Metadata
- Authors
- Schwabe, R. F., Tabas, I., & Pajvani, U. B.
- Affiliations
- Columbia University Irving Medical Center (US)
- Columbia University (US)
- Corresponding author
- Schwabe, Robert F.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 158
- Issue
- 7
- Pages
- 1913-1928
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC7682538
- OpenAlex
- W3005214954
- Cited by
- 671
- References
- 169
- Citations by year
- 2026: 82 · 2025: 121 · 2024: 138 · 2023: 131 · 2022: 117 · 2021: 53 · 2020: 27
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, liver fibrosis, hepatic stellate cells, macrophages, hepatocyte death, efferocytosis, TAZ, Notch signaling, Hedgehog signaling, single-cell RNA sequencing, antifibrotic therapy, non-alcoholic fatty liver disease
- MeSH terms
- Animals, Cell Communication, Extracellular Matrix, Humans, Liver, Liver Cirrhosis, Macrophages, Signal Transduction, Cell Death, Hepatocytes, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
